<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Numerous epidemiological studies have consistently demonstrated the strong association between type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) and an increased risk to develop <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The pathogenesis of T2DM and its complications are characterized by pancreatic, adipose tissue and <z:mp ids='MP_0001863'>vascular inflammation</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>CD40 and CD40L, members of the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (receptor) TNF(R) family, are well known for their role in immunity and <z:mp ids='MP_0001845'>inflammation</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>Here we give an overview on the role of CD40-CD40L interactions in the pathogenesis of T2DM with a special focus on pancreatic, adipose tissue and <z:mp ids='MP_0001863'>vascular inflammation</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>In addition, we explore the role of soluble CD40L (sCD40L) as a potential biomarker for the development of <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in T2DM subjects </plain></SENT>
<SENT sid="5" pm="."><plain>Finally, the therapeutic potential of CD40-CD40L inhibition in T2DM is highlighted </plain></SENT>
</text></document>